Michael Wang, Luis Fayad, Fernando Cabanillas, Fredrick Hagemeister, Peter McLaughlin, Maria A Rodriguez, Larry W. Kwak, Yuhong Zhou, Hagop Kantarjian and Jorge Romaguera Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma Cancer 113
Article first published online: 30 OCT 2008 | DOI: 10.1002/cncr.23880
Relapsed and refractory mantle cell lymphoma has a poor prognosis, but donor transplants with reduced intensity conditioning regimens offer hope, especially in patients who achieve remission to salvage chemotherapy. An intense salvage regimen could increase the chances of obtaining a complete remission and thus improve outcome.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.